2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
List view / Grid view
Filter the results
An integrated Phase I/III trial has enrolled its first patient to test a biosimilar for denosumab to treat postmenopausal osteoporosis.
The drug denosumab was superior to a commonly used drug in a 12-month study enrolling 795 patients...